| Xeomin (incobotulinumtoxinA) / Merz Pharma |
2016-001378-13: A randomized, sham-controlled trial which compare the deep brain stimulation of a specific brain region against a conventional botulinum toxine treatment for cervical dystonia. Eine randomisierte, scheinkontrollierte Studie, die die tiefe Hirnstimulation eine speziellen Hirnregion mit einer herkömmlichen Botulinumtoxintherapie bei zervikaler Dystonie vergleicht. |
|
|
| Not yet recruiting | 4 | 66 | Europe | Botulinumtoxin Type A, Powder for solution for injection, Botox(R) 50, Botox(R) 100, Botox(R) 200, Dysport(R) 300, Dysport(R) 500, XEOMIN(R) 50, XEOMIN(R) 100 | University Hospital Wuerzburg, Federal Ministry of Education and Research (BMBF), Medtronic GmbH | cervical dystonia zervikale Dystonie, Torticollis spasmodicus Schief- bzw. Fehlhaltung des Halses, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-001912-31: Treatment of headache attributed to temporomandibular disorder with a flat plane occlusal splint and injections of botulinum toxin Zdravljenje glavobola v zvezi s temporomandibularno motnjo z Michigansko okluzijsko opornico in injekcijami botulinum toksina |
|
|
| Not yet recruiting | 4 | 120 | Europe | Botox, Powder for suspension for injection, XEOMIN 100 units powder for solution for injection | UNIVERSITY MEDICAL CENTRE LJUBLJANA, UNIVERSITY MEDICAL CENTRE LJUBLJANA | Headache attributed to temporomandibular disorder Glavobol v zvezi s temporomandibularno motnjo, Headache caused by a disorder involving structures in the temporomandibular region. Glavobol, ki ga povzroča motnja, ki vključuje strukture v temporomandibularni regiji., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
| Not yet recruiting | 4 | 6 | Europe | Incobotulinumtoxin A (BTX A) Xeomin® | Dominik Ettlin, Merz Pharmaceuticals | Sleep Bruxism, Adult | 12/22 | 06/23 | | |
| Recruiting | 4 | 20 | US | Xeomin®, IncobotulinumtoxinA | Wake Forest University Health Sciences, Merz Pharmaceuticals GmbH | Stroke | 04/26 | 04/26 | | |
2021-001634-18: A clinical study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy Badanie kliniczne mające na celu zbadanie skuteczności i bezpieczeństwa stosowania NT 201 w leczeniu spastyczności kończyn dolnych u dzieci i młodzieży z mózgowym porażeniem dziecięcym |
|
|
| Not yet recruiting | 3 | 130 | Europe | NT 201, NT 201, Powder for solution for injection, Xeomin | Merz Pharmaceuticals GmbH, Merz Pharmaceuticals GmbH | Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP) Spastyczność kończyn dolnych u dzieci z mózgowym porażeniem dziecięcym., Pediatric lower limb spasticity caused by cerebral palsy. Spastyczność kończyn dolnych u dzieci z mózgowym porażeniem dziecięcym., Diseases [C] - Nervous System Diseases [C10] | | | | |
2016-003949-28: Efficacy and tolerability of incobotulinumtoxin A in comparison with onabotulinumtoxinA in patients with overactive bladder syndrome. Efficacia e tollerabilit¿ della incobotulinumtoxin A in confronto alla onabotulinumtoxin A nella terapia di pazienti con vescica iperattiva. |
|
|
| Not yet recruiting | 3 | 140 | Europe | xeomin, botox, Powder for solution for injection, XEOMIN - 100 UNITA' DL50 POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO DI VETRO, BOTOX - 100 UNIT¿ ALLERGAN POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO | PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA, Clinica Urologica ad indirizzo Oncologico | neurogenic overactive bladder Vescica iperattiva neurogena, neurogenic overactive bladder Vescica iperattiva neurogena, Diseases [C] - Symptoms and general pathology [C23] | | | | |
2019-004113-13: Safety and efficacy study of the simultaneous treatment of upper facial lines (horizontal forehead lines, glabellar frown lines and crows feet) in subjects with moderate to severe upper facial lines. |
|
|
| Not yet recruiting | 3 | 360 | Europe | Bocouture, NT 201, Powder for solution for injection, Bocouture (100 Units) | Merz Pharmaceuticals GmbH, Merz Pharmaceutical GmbH | Moderate to severe upper facial lines(horizontal forehead lines, glabellar frown lines, and lateral canthal lines), Moderate to severe upper facial lines(horizontal forehead lines, glabellar frown lines, and crows feed Falten des oberen Gesichtsbereiches(horizontale Stirnfalten, Zornesfalten und Krähenfüße), Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Recruiting | 3 | 220 | Europe | Botulinum Toxin Type A Injection [Xeomin], Xeomin, Drug placebo | Assistance Publique - Hôpitaux de Paris, Merz Pharmaceuticals, Ministry of Health, France | Cardiac Surgery | 10/24 | 09/25 | | |
2020-006147-25: Botulinum toxin type A injection in patients with chronic pelvic pain of uterine origin Phase III, single-center, randomized study vs. control group Injection de Toxine botulinique de type A chez des patientes atteintes de douleurs pelviennes chroniques d’origine utérine Étude de phase III, monocentrique, randomisée vs groupe contrôle |
|
|
| Ongoing | 3 | 100 | Europe | Toxine botulinique, Powder for solution for injection, XEOMIN 200 | Centre de Recherche en Santé de la Femme, Centre de Recherche en Santé de la Femme, Laboratoire MERZ | PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4 PATIENTES PRÉSENTANT DES DOULEURS PELVI-PERINEALES CHRONIQUES D'ORIGINE UTÉRINE AVEC EVA>4, PATIENTS WITH CHRONIC PELVIC PERINEAL PAIN OF UTERINE ORIGIN WITH VAS>4 PATIENTES PRÉSENTANT DES DOULEURS PELVI-PERINEALES CHRONIQUES D'ORIGINE UTÉRINE AVEC EVA>4, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
NCT05623410: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines |
|
|
| Active, not recruiting | 3 | 300 | RoW | ATGC-110, Clostridium Botulinum Type A, Xeomin®, Incobotulinumtoxin A | ATGC Co., Ltd. | Glabellar Frown Lines | 02/23 | 06/23 | | |
NCT06205797: To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III) |
|
|
| Not yet recruiting | 3 | 312 | NA | HU-045, Xeomin® | Huons Biopharma | Glabellar Lines | 09/24 | 07/25 | | |
PATTERN, NCT03992404 / 2018-001639-35: Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury |
|
|
| Recruiting | 3 | 600 | Europe, US, RoW | NT 201, IncobotulinumtoxinA, Incobotulinumtoxin A, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, Placebo | Merz Pharmaceuticals GmbH | Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury | 08/25 | 04/27 | | |
| Completed | 2 | 50 | RoW | HU-045, IncobotulinumtoxinA, Xeomin® | Huons Co., Ltd. | Glabellar Lines | 11/22 | 04/23 | | |
NCT04766723: A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm |
|
|
| Completed | 2 | 78 | Europe, Canada, US | NT 201, Incobotulinumtoxin A, IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, Placebo | Merz Pharmaceuticals GmbH | Essential Tremor of the Upper Limb | 04/23 | 11/23 | | |
NCT05456087: Use of Botulinum Toxin in the Treatment of Androgenic Alopecia |
|
|
| Active, not recruiting | 2 | 20 | US | incobotulinumtoxin A, Xeomin | Zel Skin and Laser Specialists, Merz Aesthetics Inc. | Androgenetic Alopecia | 12/24 | 12/24 | | |
| Completed | 2 | 68 | US | NT 201, IncobotulinumtoxinA, Xeomin/Bocouture, Xeomin Cosmetic, Xeomeen, NT 201 Placebo | Merz Aesthetics GmbH | Platysma Prominence | 10/23 | 01/24 | | |
2021-001988-24: A Study to Investigate the Efficacy and Safety of NT201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm |
|
|
| Not yet recruiting | 2 | 75 | Europe | NT 201, NT 201, Powder for solution for injection, Xeomin | Merz Pharmaceuticals GmbH, Merz Pharmaceuticals GmbH | Essential tremor [ET] of the upper limb [UL], Essential tremor [ET] of the upper limb [UL], Diseases [C] - Nervous System Diseases [C10] | | | | |
PaiNT, NCT06091020: A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury |
|
|
| Recruiting | 2 | 120 | Europe | IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, NT 201, Placebo | Merz Therapeutics GmbH | Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury | 01/25 | 04/25 | | |
PINBOT, NCT05623111: Perineural Injections of Incobotulinumtoxin-A for Diabetic Neuropathic Pain of the Lower Extremities |
|
|
| Recruiting | 2 | 80 | Europe | Incobotulinumtoxin-A 100 UNIT Injection, Saline | Rigshospitalet, Denmark, Merz Pharmaceuticals GmbH, Toyota Foundation Denmark, Steno Diabetes Center Zealand Region, Shipwright Per Henriksen, R., and wife Foundation | Diabetic Neuropathy, Painful | 11/25 | 02/26 | | |
NCT05305768: Xeomin Treatment of Glabellar Lines Using OLD Versus COLD |
|
|
| Not yet recruiting | 1 | 40 | US | IncobotulinumtoxinA, Xeomin | Clinical Testing of Beverly Hills, Merz North America, Inc. | Glabellar Frown Lines | 02/23 | 02/23 | | |
NCT05585398: A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods |
|
|
| Completed | 1 | 40 | Europe | IncobotulinumtoxinA, Xeomin, Botulinum toxin type A (150 kiloDalton), free from complexing proteins | Merz Pharmaceuticals GmbH | N/A, as no Specific Medical Condition Will be Treated | 02/23 | 04/23 | | |
LESS, NCT05784363: A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face |
|
|
| Completed | 1 | 31 | US | NT 201, IncobotulinumtoxinA, Xeomin/Bocouture®, Xeomin Cosmetic, Xeomeen, Placebo | Merz North America, Inc. | Enlarged Pores, Sebum Production | 06/24 | 07/24 | | |
NCT05222607: Longitudinal Evaluation and Real-world Evidence of NT201 |
|
|
| Terminated | N/A | 11 | US | IncobotulinumtoxinA, XEOMIN®, BOCOUTURE® | Merz North America, Inc. | Glabellar Frown Lines and Canthal Lines and/or Horizontal Forehead Lines in the Upper Face | 05/23 | 05/23 | | |
XAVIER, NCT06345677: Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects |
|
|
| Completed | N/A | 48 | Europe | ViXe Xombination, Placebo + Sham | Vensica Therapeutics Ltd., Blueclinical, Ltd. | Overactive Bladder | 02/24 | 02/24 | | |
| Completed | N/A | 270 | Europe | CC BoNT/A, onabotulinumtoxinA, abobotulinumtoxinA, CF BoNT/A, incobotulinumtoxinA, NT 201, Botulinum toxin type A (150 kiloDalton), free from complexing proteins, CF to CC BoNT/A, CC to CF BoNT/A | Merz Therapeutics GmbH, Heinrich-Heine University, Duesseldorf | Cervical Dystonia | 05/24 | 07/24 | | |